CentoNIPT® - Non invasive prenatal testing at CENTOGENE
Illumina VeriSeq™ NIPT Solution*
Conventional prenatal testing for fetal chromosomal abnormality involves either chorionic villus sampling or amniocentesis. These procedures are highly invasive and carry an elevated risk of miscarriage, but despite this have become standard practice worldwide due to their high levels of accuracy and the range of abnormalities they can detect.
With CentoNIPT® CENTOGENE now offers non-invasive prenatal testing that provides a fast and accurate screen for the most common prenatal chromosomal abnormalities.
CentoNIPT® is performed on a single maternal blood sample and combines the latest next generation sequencing technology with the highest quality medical reporting. It provides unparalleled accuracy and detection compared to other non-invasive testing methods – ultrasonography or nuchal translucency testing.
Our medical expertise is ideally suited to provide you and your patients with reliable, well supported result interpretation.
Fetal chromosomal abnormalities
- Approximately 1% of all babies will be born with a chromosomal abnormality causing physical disability and/or mental retardation
- 70% of syndromic congenital abnormalities are contributed by Trisomy T21, T18 or T13 and 10% by Turner syndrome (Monosomy X)
- The risk of trisomy increases significantly with maternal age
|Trisomy 21 (Down syndrome)||98.9%||>99.9%|
|Trisomy 18 (Edwards syndrome)||90.0%||99.9%|
|Trisomy 13 (Patau syndrome)||100.0%||99.9%|
Sex chromosome aneuploidies & fetal gender
|Concordance with cytogenetic results|
|X0 (Turner syndrome)||100.0 %|
|XXX (Triple X syndrome)||80.0 %|
|XXY (Klinefelter syndrome)||100.0 %|
|XYY (Jacobs syndrome)||100.0 %|
Why choose CENTOGENE?
100% safe for mother & child
Only 9ml of maternal blood required
Test as early as possible
From the 10th gestational week
Fast & reliable results
Results within 5 working days
Latest NGS technology and high-quality medical reporting
Your CentoNIPT® set is provided and shipped free of charge.
For return shipment just a phone call is needed.
Prepare the maternal sample
Select your test in CentoPortal® by using the NI code on the Streck tube provided
Pack and ship the sample in your CentoNIPT® box free of charge
Sample processing and results within 5 days
Your experts in prenatal diagnostics
Fast & accurate results
Our optimized workflows provide a full medical report within 5 working days from high-quality, validated results.
High sensitivity & specificity
CentoNIPT® combines next generation sequencing with integrated measurement of fetal fraction, even at fetal fraction < 4%. This concludes in the lowest technical failure rate and unnecessary invasive testing as follow-up of NIPT tests available.
The CENTOGENE advantage
CENTOGENE offers a comprehensive package starting with NIPT for most common chromosome aneuploidies to prenatal whole exome / whole genome sequencing. After birth, we offer biomarker testing and our whole genetic test portfolio including specialized genetic analysis for critically ill newborns on ICU.
Frequently asked questions
CentoNIPT® is based on the in vitro diagnostic test Illumina VeriSeq™ NIPT Solution. This noninvasive IVD test utilizes whole-genome sequencing on cell-fetal DNA (cfDNA) fragments derived from maternal peripheral whole blood samples. After whole genome sequencing and bioinformatics analysis, chromosome read numbers and fetal fraction are combined and thus translated into chromosome ploidy. Finally, the comparison of the tested chromosomes by this test (21, 18, 13, X and Y) with reference chromosomes enables the identification of aneuploidies, which are then reported.
We report aneuploidy, the occurrence of additional chromosomes in the fetus. However, this analysis is restricted to those chromosomes where a living fetus could be born with abnormalities. These chromosomes include chromosome 13, 18, 21 and the sex chromosomes.
The analysis only reports if an additional chromosome has been identified
YES – the data indicate an extra copy of one chromosome. Invasive prenatal genetic testing must will need to be performed to confirm the genetic diagnosis.
NO – the data do not indicate any extra copy of the aforementioned chromosomes.
Yes. However, the gender information will be provided only after 12 weeks of gestation, as regulated by German law, as the test is performed in Germany.
Yes. The fetal fraction is included in the result.
This analysis is restricted to fetal cells from the placenta and not from the fetus itself. Fetoplacental mosaicism, a different chromosomal setup for placenta and fetus, is very rare but cannot be ruled out. Although sensitivity and specificity of NIPT are indeed high, it is necessary to confirm such results by additional method(s), such as echosonographic findings, maternal serum analysis; or perhaps amniocentesis for confirmation of a positive result.
Notation: *Sample Preparation and analysis software are CE-IVD marked
Noninvasive prenatal testing (NIPT) based on cell-free DNA analysis from maternal blood is a screening test; it is not diagnostic. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision.